Literature DB >> 15170094

Progressive nature of paroxysmal atrial fibrillation. Observations from a 14-year follow-up study.

Takeshi Kato1, Takeshi Yamashita, Kouichi Sagara, Hiroyuki Iinuma, Long-Tai Fu.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is believed to occur first as paroxysmal, then be gradually perpetuated, and finally become chronic as the end result. However, this presumed clinical course has not been well confirmed. METHODS AND
RESULTS: The clinical course of recurrent paroxysmal AF (PAF) from its onset was examined in 171 patients (mean follow-up period: 14.1+/-8.1 years). This study population consisted of patients with no structural heart disease (n=88), ischemic heart disease (n=28), dilated or hypertrophic cardiomyopathy (n=17), valvular heart disease (n=35) or other cardiac diseases. The mean age at the onset of AF was 58.3 +/-11.8 years old. During the mean follow-up period of 14.1 years, PAF eventually developed into its chronic form in 132 patients under conventional antiarrhythmic therapy (77.2%, 5.5% of patients per year). The independent factors for early development into chronic AF were aging (hazard ratio (HR) 1.27 per 10 years, 95% confidence interval (CI) 1.06-1.47)), dilated left atrium (HR 1.39 per 10 mm, 95% CI 1.11-1.69), myocardial infarction (HR 2.33, 95% CI 1.13-4.81), and valvular diseases (HR 2.29, 95% CI 1.22-4.30).
CONCLUSIONS: The present long-term observations definitely and quantitatively revealed the progressive nature of PAF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15170094     DOI: 10.1253/circj.68.568

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  32 in total

1.  Can we ablate permanent atrial fibrillation?

Authors:  G Haywood
Journal:  Heart       Date:  2005-11-24       Impact factor: 5.994

2.  Atrial fibrillation and oral anticoagulation in older people with frailty: a nationwide primary care electronic health records cohort study.

Authors:  Chris Wilkinson; Andrew Clegg; Oliver Todd; Kenneth Rockwood; Mohammad E Yadegarfar; Chris P Gale; Marlous Hall
Journal:  Age Ageing       Date:  2020-12-16       Impact factor: 10.668

Review 3.  [Pulmonary vein isolation for atrial fibrillation : Findings from long-term follow-up].

Authors:  C-H Heeger; K-H Kuck; F Ouyang
Journal:  Herz       Date:  2017-06       Impact factor: 1.443

4.  A novel association of adenosine deaminase with paroxysmal atrial fibrillation: a propensity score analysis from a case-control study.

Authors:  Liang Liu; Yong-Ming He; Cui-Fen Hu; Xin Zhao; Hai-Feng Xu; Xiang-Jun Yang
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

Review 5.  Antiarrhythmic therapy of atrial fibrillation: are we treating too late?

Authors:  Kristina Wasmer; Julia Köbe; Lars Eckardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2014-08-21

Review 6.  The Role of Echocardiography as a Predictor of the Incidence and Progression of Atrial Fibrillation.

Authors:  Rui Providência; Sérgio Barra; Luís Paiva
Journal:  J Atr Fibrillation       Date:  2012-10-06

Review 7.  Comparing Antiarrhythmic Drugs and Catheter Ablation for Treatment of Atrial Fibrillation.

Authors:  Andreas Rillig; Tina Lin; Feifan Ouyang; Karl Heinz Kuck; Roland Richard Tilz
Journal:  J Atr Fibrillation       Date:  2013-06-30

8.  Evolution of Paroxysmal Atrial Fibrillation to Persistent or Permanent Atrial Fibrillation: Predictors of Progression.

Authors:  Jayasree Pillarisetti; Akshar Patel; Kenneth Boc; Sudharani Bommana; Youssef Sawers; Subbareddy Vanga; Hari Sayana; Warren Chen; Jayanth Nath; James Vacek; Dhanunjaya Lakkireddy
Journal:  J Atr Fibrillation       Date:  2009-06-01

Review 9.  Early Cardioversion in Atrial Fibrillation: Earlier Is Better, but Not Always and (Maybe) Not Immediately.

Authors:  Paloma G Piña; Alexandru B Chicos
Journal:  Curr Atheroscler Rep       Date:  2017-01       Impact factor: 5.113

10.  An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality.

Authors:  Etienne Aliot; Günter Breithardt; Josep Brugada; John Camm; Gregory Y H Lip; Panos E Vardas; Markus Wagner
Journal:  Europace       Date:  2010-05       Impact factor: 5.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.